Abstract 7299: CS2009: A first-in-class trispecific antibody targeting PD-1, CTLA-4, and VEGFA with potential to be a next-generation backbone therapy with combined checkpoint inhibition and anti-angiogenesisChuan Wang, Jianxin Yang, Xueqin Dai et al.|Cancer Research|2025Cited by 4